Deltex Medical Group plc (LON:DEMG) has made the first sale of one of its surgical blood monitoring systems for veterinary use.
The £15,000 sale is to a leading European veterinary university and comprises an adaption of Deltex’s Oesophageal Doppler Monitoring (ODM) platforrm CardioQ-ODM+ using specially designed probes.
The K9 probes (and ODMV+ monitors) are designed for smaller animals such as dogs and cats and allow multiple uses for up 30 days, which can be used as a per case billing model for veterinary practices.
Deltex is planning the marketing launch of the new system for the annual meeting of the International Veterinary Emergency and Critical Care Symposium in Nashville in September.
Ewan Phillips, Deltex’s chief executive, said: "We are delighted to have made our first sale of the ODMV+ system simultaneously with its release.
“ODM is ideally suited for use in animals who tend to have high degrees of haemodynamic instability during surgery and in critical care.
"We have a small number of other customers already interested in the system and expect to generate further interest after the market launch at IVECCS at which there will be presentations from a number of experts who have been working with Deltex on developing the ODMV+.
“Our medium term goal is to develop the veterinary business to a stage where it is sold through specialist distributors."
Shares rose 13% to 4.1p.
--updates for share price--